Trevi Therapeutics Inc Market Cap ($1.83 Billion)
Market Cap & Net Worth: Trevi Therapeutics Inc (TRVI)
Trevi Therapeutics Inc market cap. Trevi Therapeutics Inc (NASDAQ:TRVI) has a market capitalization of $1.83 Billion ($1.83 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6215 globally and #2004 in its home market, demonstrating a 4.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Trevi Therapeutics Inc's stock price $13.56 by its total outstanding shares 142475841 (142.48 Million).
Trevi Therapeutics Inc Market Cap History (2019–2026)
Trevi Therapeutics Inc market cap history from 2019 to 2026. Data shows growth from $534.28 Million to $1.93 Billion (7.50% CAGR). Check latest Trevi Therapeutics Inc stock price today for real-time trading data and today's change.
Index Memberships
Trevi Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.07% | #177 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #703 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.10% | #106 of 263 |
Weight: Trevi Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Trevi Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Trevi Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of Trevi Therapeutics Inc for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TRVI by Market Capitalization
Companies near Trevi Therapeutics Inc in the global market cap rankings as of October 31, 2026. See TRVI equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Trevi Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Trevi Therapeutics Inc (2019–2026)
Market capitalization of Trevi Therapeutics Inc from 2019 to today. Between 2019 and today, Trevi Therapeutics Inc's market cap moved from $534.28 Million to $ 1.93 Billion, with a yearly change of 7.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.93 Billion | +8.31% |
| 2025 | $1.78 Billion | +203.88% |
| 2024 | $587.00 Million | +207.46% |
| 2023 | $190.92 Million | -30.57% |
| 2022 | $274.98 Million | +146.80% |
| 2021 | $111.42 Million | -67.69% |
| 2020 | $344.79 Million | -35.47% |
| 2019 | $534.28 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Trevi Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.83 Billion USD |
| MoneyControl | $1.83 Billion USD |
| MarketWatch | $1.83 Billion USD |
| marketcap.company | $1.83 Billion USD |
| Reuters | $1.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more